AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in combination with standard-of-care radiotherapy ...
Apr 9, 2024
0
1
Accumulation of pathologic tau protein plays a pivotal role in the neurodegeneration of Alzheimer's disease (AD) and many other tauopathies. Thus, amelioration of pathological tau aggregates in the brain is an important direction ...
Mar 28, 2024
0
0
Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced ...
Mar 27, 2024
0
0
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed ...
Mar 19, 2024
0
3
Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators. They have conducted the first whole genome sequencing ...
Mar 4, 2024
0
0
Specific combinations of antihypertensives are recommended for patients with Bruton's tyrosine kinase inhibitor (BTKi)-associated hypertension (HTN), according to a study published online Feb. 5 in Blood Advances.
Feb 19, 2024
0
0
Researchers from the University of Missouri School of Medicine have found potential treatments for two different types of common complications following bone marrow transplantation.
Feb 14, 2024
0
0
For some leukemia patients, the only potential chemotherapy option is a drug that also carries a high risk of heart failure. This means that some patients who recover from their cancer will end up dying of heart disease brought ...
Feb 8, 2024
0
0
Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new study published in Blood Advances.
Feb 5, 2024
0
0
Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years ...
Dec 11, 2023
0
0
